Cognition Therapeutics, Inc. announced that the company has been awarded a Therapeutic Pipeline Program Grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). This grant will fund preclinical studies of two sigma-2 (s-2) receptor modulators in animal models of Parkinson's disease that will be led by Cognition Therapeutics' VP of research, Mary E. Hamby, Ph.D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.98 USD | +3.12% |
|
-3.88% | +7.03% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.03% | 79.32M | |
+20.17% | 126B | |
+24.67% | 118B | |
+25.44% | 27.87B | |
-17.74% | 20.95B | |
-15.17% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |
- Stock Market
- Equities
- CGTX Stock
- News Cognition Therapeutics, Inc.
- Cognition Therapeutics, Inc. Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson's Disease